Gemcitabine/radiation shows sustained success for bladder preservation in MIBC

In patients with muscle-invasive bladder cancer, gemcitabine plus once daily radiation showed a low cystectomy rate and high overall survival rate at long-term follow-up.

Radiotracer fluciclovine (18F) PET leads to improved cancer control in recurrent prostate cancer

EMPIRE-1 is the first randomized trial to demonstrate an improvement in failure-free survival with treatment based on advanced molecular imaging versus conventional imaging in men with recurrent prostate cancer.

FDA grants breakthrough designation to urine-based liquid biopsy for prostate cancer

The miR Sentinel PCC4 Assay is a non-invasive test that has achieved sensitivity and specificity rates above 90% for both detecting and classifying prostate tumors.

FDA grants nivolumab/cabozantinib combo priority review in kidney cancer

October 19, 2020

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.